Showing posts with label carfilzomib. Show all posts
Showing posts with label carfilzomib. Show all posts
Wednesday, January 25, 2017

Carfilzomib therapy shows promise for pre-kidney transplant patients

›
In continuation of my update on  carfilzomib , Early findings by researchers at the University of Cincinnati (UC) College of Medicine ...
Tuesday, August 9, 2016

Novel combination of cancer drugs can have therapeutic impact on diffuse large B-cell lymphoma

›
In continuation of my update on  carfilzomib ,  JQ1  and   ABT 199 New research from Roswell Park Cancer Institute (RPCI) shows that...
Wednesday, February 10, 2016

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

›
In continuation of my update on carfilzomib Carfilzomib significantly improves outcomes in previously treated patients with relap...
Saturday, August 11, 2012

Three-drug regimen provides rapid, durable responses for multiple myeloma

›
In continuation of my update on three drug combination A three-drug treatment for the blood cancer multiple myeloma provided rapid, d...
Saturday, December 17, 2011

Drug combination highly effective for newly diagnosed myeloma patients......

›
A three-drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly dia...
Tuesday, August 10, 2010

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

›
 In continuation of my update on Carfilzomib   The International Myeloma Foundation (IMF), the oldest and largest foundation dedica...
Friday, December 11, 2009

Carfilzomib for multiple myeloma ?

›
The proteasome has emerged as an important target for cancer therapy with the approval of bortezomib , a first-in-class, reversible prote...